Journal of Vascular Surgery
Volume 47, Issue 3 , Pages 537-542 , March 2008

Safety and efficacy of intravenous enoxaparin for carotid endarterectomy: A prospective randomized pilot trial

  • Afshin Assadian, MD

      Affiliations

    • Department of General and Vascular Surgery, Wilhelminenspital, Vienna, Austria
    • Corresponding Author InformationCorrespondence: Afshin Assadian, MD, Department of General and Vascular Surgery, Wilhelminenspital Vienna, Montleartstraße 37, A-1160 Vienna, Austria.
    • ,
  • Paul Knöbl, MD

      Affiliations

    • Department of Medicine I, Medical University, Vienna, Austria
    • ,
  • Wolfgang Hübl, MD

      Affiliations

    • Department of Laboratory Medicine, Wilhelminenspital, Vienna, Austria
    • ,
  • Christian Senekowitsch, MD

      Affiliations

    • Department of General and Vascular Surgery, Wilhelminenspital, Vienna, Austria
    • ,
  • Anton Klingler, PhD

      Affiliations

    • Assign Data Management and Biostatistics GmbH, Innsbruck, Austria.
    • ,
  • Norbert Pfaffelmeyer, MD

      Affiliations

    • Department of Neurology, Wilhelminenspital, Vienna, Austria
    • ,
  • Georg W. Hagmüller, MD

      Affiliations

    • Department of General and Vascular Surgery, Wilhelminenspital, Vienna, Austria

Received 16 July 2007 ,Accepted 27 October 2007.

References 

  1. Murray DWG. Heparin in surgical treatment of blood vessels. Arch Surg. 1940;40:307
  2. Norgren L Swedish EnoxaVasc Study Group. Can low molecular weight heparin replace unfractionated heparin during peripheral arterial reconstruction? (An open label prospective randomized controlled trial). J Vasc Surg. 2004;39:977–984
  3. Assadian A, Senekowitsch C, Assadian O, Eidher U, Hagmüller GW, Knöbl P. Antithrombotic strategies in vascular surgery: evidence and practice. Eur J Vasc Endovasc Surg. 2005;29:516–521
  4. Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al. Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation. 2004;109:1476–1481
  5. Poisik A, Heyer EJ, Solomon RA, Quest DO, Adams DC, Baldasserini CM, et al. Safety and efficacy of fixed dose heparin in carotid endarterectomy. Neurosurgery. 1999;45:434–441
  6. Hirsh J, van Aken WG, Gallus AS, Dollery CT, Cade JF, Yung WJ. Heparin kinetics in venous thrombosis and pulmonary embolism. Circulation. 1976;53:691–695
  7. Montalescot G, White HD, Gallo R, Cohen M, Steg PG, Aylward PE, et al. STEEPLE Investigators Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med. 2006;355:1006–1017
  8. North American Symptomatic Carotid Endarterectomy trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. N Engl J Med. 1991;325:445–453
  9. Sabeti S, Schillinger M, Mlekusch W, Willfort A, Haumer M, Nachtmann T, et al. Quantification of internal carotid artery stenosis with duplex us: comparative analysis of different flow velocity criteria. Radiology. 2004;232:431–439
  10. Nicolaides AN, Shifrin EG, Bradbury A, Dhanjil S, Griffin M, Belcaro G, et al. Angiographic and duplex grading of internal carotid stenosis: can we overcome the confusion?. J Endovasc Surg. 1996;3:158–165
  11. Young FB, Weir CJ, Lees KR GAIN International Trial Steering Committee and Investigators. Comparison of the National Institutes of Health Stroke Scale with disability outcome measures in acute stroke trials. Stroke. 2005;36:2187–2192
  12. Warketin TE. An overview of the heparin induced thrombocytopenia syndrome. Semin Thromb Hemost. 2004;30:273–283
  13. Forsell C, Takolander R, Bergquist D, Johansson A, Person NH. Local versus general anaesthesia in carotid surgery (A prospective randomized study). Eur J Vasc Surg. 1989;3:503–509
  14. Jones HU, Huhlenstein JB, Jones KW, Bair TL, Lavasani F, Shrevardi M, et al. Preoperative use of enoxaparin compared with unfractionated heparin increases the incidence of re-exploration for postoperative bleeding after open-heart surgery in patients who present with an acute coronary syndrome: clinical investigation and reports. Circulation. 2002;106(12 suppl 1):I19–I22
  15. White HD, Kleiman NS, Mahaffey KW, Lokhnygina Y, Pieper KS, Chiswell K, et al. Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa Inhibitors (SYNERGY) trial. Am Heart J. 2006;152:1042–1050
  16. Assadian A, Senekowitsch C, Assadian O, Ptakovsky H, Hagmüller GW. Perioperative morbidity and mortality of carotid artery surgery under loco-regional anaesthesia. VASA. 2005;34:41–45
  17. Lane DA, Pejler G, Flynn AM, Thompson EA, Lindahl U. Neutralization of heparin-related saccharides by histidine-rich glycoprotein and platelet factor 4. J Biol Chem. 1986;261:3980–3986
  18. Rucinsky B, Niewiaroski S, Strzyzewski M, Holt JC, Mayo KH. Human platelet factor 4 and its C-terminal peptides: heparin binding and clearance from the circulation. Thromb Haemost. 1990;63:493–498
  19. Lijnen HR, Hoylaerts M, Collen D. Heparin binding properties of human histidine-rich glycoprotein: mechanism and role in the neutralization of heparin in plasma. J Biol Chem. 1983;258:3803–3808
  20. Preissner KT, Muller-Berghaus G. Neutralization and binding of heparin by S-protein/vitronectin in the inhibition of factor Xa by antithrombin III. J Biol Chem. 1987;262:12247–12253
  21. A Pepper DS, Dawes J. Interaction of immobilised unfractionated and LMW heparins with proteins in whole human plasma. Thromb Haemost. 1993;70:951–958
  22. Self DD, Bryson GL, Sullivan PJ. Risk factors for post-carotid endarterectomy hematoma formation. Can J Anaesth. 1999;46:635–640
  23. Coyne TJ, Wallace MC, Benedict C. Peri-operative anticoagulant effects of heparinization for carotid endarterectomy. Aust N Z J Surg. 1994;64:679–683
  24. Hirsh J, Raschkr R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):188S–203S
  25. Aslam MS, Sundberg S, Sabri MN, Cooke D, Lakier JB. Pharmacokinetics of intravenous/subcutaneous enoxaparin in patients with acute coronary syndrome undergoing percutaneous coronary interventions. Catheter Cardiovasc Interv. 2002;57:187–190
  26. Sanchez-Pena P, Hulot JS, Urien S, Ankari A, Collet JP, Choussat R, et al. Anti-factor Xa kinetics after intravenous enoxaparin in patients undergoing percutaneous coronary intervention: a population model analysis. Br J Clin Pharmacol. 2005;60:364–373
  27. Young E, Wells P, Holloway S, Weitz J, Hirsh J. Ex-vivo and in vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost. 1994;71:300–304

 Competition of interest: The study was supported by a scientific grant by Sanofi-Aventis Austria, who is the manufacturer and distributor of enoxaparin.

PII: S0741-5214(07)01759-4

doi: 10.1016/j.jvs.2007.10.055

Journal of Vascular Surgery
Volume 47, Issue 3 , Pages 537-542 , March 2008

Article Tools

* Image Usage & Resolution